The role of biologic therapies in the management of systemic vasculitis

Autoimmunity Reviews

Volumn 5, Issue 4, 2006, Pages 273-278

  Chan, A T ^a   Flossmann O ^b   Mukhtyar, C ^a   Jayne, D R W ^b   Luqmani, R A ^a  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Biologic agents; Connective tissue disease; Systemic vasculitis; TNF ; TNF inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL FACTOR; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; AORTA ARCH SYNDROME; ARTERY THROMBOSIS; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CRYOGLOBULINEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG MEGADOSE; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TREATMENT FAILURE; GIANT CELL ARTERITIS; HEPATITIS B; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG HEMORRHAGE; LYMPHOCYTOPENIA; MUCOCUTANEOUS LYMPH NODE SYNDROME; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; POLYARTERITIS NODOSA; PREDICTION; REMISSION; RETINA ARTERY OCCLUSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; VASCULITIS;

EID: 33646369631     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.01.003     Document Type: Review

References (40)

1. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343 22 (2000) 1594-1602
2. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 53 3 (1999) 457-465
3. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 4 (2005) 351-361
4. Stone J.H., Uhlfelder M.L., Hellmann D.B., Crook S., Bedocs N.M., and Hoffman G.S. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44 5 (2001) 1149-1154
5. Jaskowski T.D., Martins T.B., Litwin C.M., and Hill H.R. Comparison of four enzyme immunoassays for the detection of immunoglobulin G antibody against glomerular basement membrane. J Clin Lab Anal 16 3 (2002) 143-145
6. Genovese M.C., Bathon J.M., Fleischmann R.M., Moreland L.W., Martin R.W., Whitmore J.B., Tsuji W.H., and Leff J.A. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 32 (2005) 1232-1242
7. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63 (2004) 1538-1543
8. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 10 (2002) 1126-1132
9. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 3 (2004) 717-721
10. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41 11 (2002) 1303-1307
11. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., and Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173 2 (2006) 180-187
12. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257 6 (2005) 540-548
13. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-Suarez L.F., and Van der Woude F.J. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65 4 (2004) 1440-1448
14. Lockwood C.M., Hale G., Waldman H., and Jayne D.R. Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 42 12 (2003) 1539-1544
15. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 10 2 (2005) 79-93
16. Hernandez-Rodriguez J., Segarra M., Vilardell C., Sanchez M., Garcia-Martinez A., Esteban M.J., et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43 3 (2004) 294-301
17. Wagner A.D., Bjornsson J., Bartley G.B., Goronzy J.J., and Weyand C.M. Interferon-gamma-producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 148 6 (1996) 1925-1933
18. Roche N.E., Fulbright J.W., Wagner A.D., Hunder G.G., Goronzy J.J., and Weyand C.M. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36 9 (1993) 1286-1294
19. Weyand C.M. The Dunlop-Dottridge lecture: the pathogenesis of giant cell arteritis. J Rheumatol 27 2 (2000) 517-522
20. Airo P., Antonioli C.M., Vianelli M., and Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41 3 (2002) 347-349
21. Cantini F., Niccoli L., Salvarani C., Padula A., and Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44 12 (2001) 2933-2935
22. Docken W.P. Treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 63 4 (2004) 469-470
23. Tan A.L., Holdsworth J., Pease C., Emery P., and McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 62 4 (2003) 373-374
24. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 31 7 (2004) 1467
25. Hoffman G.S., Merkel P.A., Brasington R.D., Lenschow D.J., and Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50 7 (2004) 2296-2304
26. Tatsis E., Schnabel A., and Gross W.L. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129 5 (1998) 370-374
27. Lesens O., Hansmann Y., Nerson J., Pasquali J., Gasser B., Wihlm J., et al. Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur J Intern Med 13 7 (2002) 458
28. Metzler C., Hellmich B., Gause A., Gross W.L., and de Groot K. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22 6 Suppl. 36 (2004) S52-S61
29. Avsar E., Savas B., Tozun N., Ulusoy N.B., and Kalayci C. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 28 3 (1998) 525-526
30. Kruger M., Boker K.H., Zeidler H., and Manns M.P. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 26 4 (1997) 935-939
31. Deleaval P., Stadler P., Descombes E., Hecker E., Schrago G., Chizzolini C., et al. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol 20 4 (2001) 290-292
32. Guillevin L., Lhote F., Sauvaget F., Deblois P., Rossi F., Levallois D., et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 53 5 (1994) 334-337
33. Weiss J.E., Eberhard B.A., Chowdhury D., and Gottlieb B.S. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31 4 (2004) 808-810
34. Burns J.C., Mason W.H., Hauger S.B., Janai H., Bastian J.F., Wohrley J.D., et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 146 5 (2005) 662-667
35. Chandesris M.O., Gayet S., Schleinitz N., Doudier B., Harle J.R., and Kaplanski G. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia. Rheumatology (Oxford) 43 4 (2004) 532-533
36. Koukoulaki M., Abeygunasekara S.C., Smith K.G., and Jayne D.R. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 20 1 (2005) 213-216
37. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 10 (2003) 3827-3834
38. Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19 12 (2004) 3054-3061
39. Sansonno D., De R.V., Lauletta G., Tucci F.A., Boiocchi M., and Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 10 (2003) 3818-3826
40. Arbach O., Gross W.L., and Gause A. Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade. Immunobiology 206 5 (2002) 496-501